Sign in
VIR Stock Price, Chart, Stats & News
Vir Biotechnology, Inc.
Save
1.54B
Market cap
–
Current P/E
4.27x
Forward P/E
VIR chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 99.96% |
Operating margin | -682.68% |
Pretax margin | -638.56% |
Net margin | -638.87% |
Effective tax rate | -0.05% |
ROA | -43.68% |
ROE | -49.31% |
D/E | 0.24x |
Interest coverage ratio | – |
VIR valuation
P/E | – |
P/S | 19.58x |
P/B | 1.53x |
P/CF | -2.99x |
P/FCF | -3.43x |
P/OCF | -2.99x |
PEG | -0.21x |
EV multiple | -3.08x |
About
Vir Biotechnology, Inc. operates as an immunology company with commercialized products, dedicated to devising therapeutic solutions for the treatment and prevention of significant infectious diseases. Its pipeline features several key candidates: Sotrovimab (branded as Xevudy, or VIR-7832), a neutralizing monoclonal antibody for both treating and preventing SARS-CoV-2 infection; VIR-2218 and VIR-3434, aimed at hepatitis B virus; VIR-2482, targeting the prevention of influenza A virus; and VIR-1111, designed to prevent human immunodeficiency virus. The firm maintains a robust network of strategic partnerships and collaborations.
Similar securities
Based on sector and market capitalization
Report issue